Abstract
The management of non-small cell lung cancer (NSCLC) continues to evolve as more genetic mutations and other predictive biologic markers are discovered and targeted therapies are developed. Targeted therapies such as bevacizumab, erlotinib, and crizotinib are only appropriate for select groups of patients. The use of targeted therapies is leading to more individualized therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 22-24 |
| Number of pages | 3 |
| Journal | Journal of Managed Care Medicine |
| Volume | 15 |
| Issue number | 1 |
| State | Published - Aug 23 2012 |
Fingerprint
Dive into the research topics of 'Optimizing treatment strategies in the management of non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver